Cargando…

Salvage treatment for lymph node recurrence after radical resection of esophageal squamous cell carcinoma

BACKGROUND: Patients with regional lymph node recurrence after radical resection of esophageal cancer have poor therapeutic outcomes. Currently, there is no standard treatment for regional lymph node recurrence, and its prognostic risk factors are not well-understood. This study retrospectively anal...

Descripción completa

Detalles Bibliográficos
Autores principales: Chen, Jie, Yin, Wenming, Yao, Hui, Gu, Wendong
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2019
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6749665/
https://www.ncbi.nlm.nih.gov/pubmed/31533757
http://dx.doi.org/10.1186/s13014-019-1377-y
_version_ 1783452324443717632
author Chen, Jie
Yin, Wenming
Yao, Hui
Gu, Wendong
author_facet Chen, Jie
Yin, Wenming
Yao, Hui
Gu, Wendong
author_sort Chen, Jie
collection PubMed
description BACKGROUND: Patients with regional lymph node recurrence after radical resection of esophageal cancer have poor therapeutic outcomes. Currently, there is no standard treatment for regional lymph node recurrence, and its prognostic risk factors are not well-understood. This study retrospectively analyzed 83 patients with postoperative regional lymph node recurrence after radical resection of esophageal squamous cell carcinoma. The aim was to evaluate the clinical efficacy and prognostic factors of salvage radiotherapy with or without chemotherapy in these patients. METHODS: The survival and prognostic factors of 83 patients with esophageal squamous cell carcinoma with regional lymph node recurrence after radical surgery were retrospectively analyzed. All patients underwent radiotherapy, of which 74 patients received volumetric modulated arc therapy (VMAT), 9 patients received three-dimensional conformal radiation therapy (3DCRT), administered using a conventional segmentation protocol with a dose distribution range of 50.4–66.2Gy (median dose of 60Gy). In total, 41 patients received radiotherapy alone, 42 received radiotherapy combined with chemotherapy, and the concurrent chemotherapy regimen was mainly composed of either platinum or fluorouracil monotherapy, except for 4 patients who were given 5-fluorouracil plus platinum (FP) or paclitaxel plus platinum (TP). RESULTS: The median follow-up time was 24 (range, 9–75) months. The overall survival (OS) rates at 1 year, 2 years, 3 years, and 5 years were 83.0, 57.1, 40.1, and 35.1%, respectively. The median overall survival (OS) time was 18 (range, 5–75) months. The 3-year survival rate was 47.5% in patients with radiation alone and 41.9% in patients receiving concurrent chemoradiotherapy(p = 0.570), while the response rate (CR + PR) in those two groups was 73.2 and 91.4%, respectively. By multivariate analysis of OS, age (worse in younger patients, p = 0.034) was found to be significantly associated with disease prognosis. The commonly toxicities were esophagitis, neutropenia and anemia. 18% patients experienced grade 3 toxicity and no treatment-related death occurred. CONCLUSIONS: These results of this retrospective analysis suggest that radiotherapy with or without chemotherapy is an effective and feasible salvage treatment for lymph node recurrence after radical resection of esophageal squamous cell carcinoma.
format Online
Article
Text
id pubmed-6749665
institution National Center for Biotechnology Information
language English
publishDate 2019
publisher BioMed Central
record_format MEDLINE/PubMed
spelling pubmed-67496652019-09-23 Salvage treatment for lymph node recurrence after radical resection of esophageal squamous cell carcinoma Chen, Jie Yin, Wenming Yao, Hui Gu, Wendong Radiat Oncol Research BACKGROUND: Patients with regional lymph node recurrence after radical resection of esophageal cancer have poor therapeutic outcomes. Currently, there is no standard treatment for regional lymph node recurrence, and its prognostic risk factors are not well-understood. This study retrospectively analyzed 83 patients with postoperative regional lymph node recurrence after radical resection of esophageal squamous cell carcinoma. The aim was to evaluate the clinical efficacy and prognostic factors of salvage radiotherapy with or without chemotherapy in these patients. METHODS: The survival and prognostic factors of 83 patients with esophageal squamous cell carcinoma with regional lymph node recurrence after radical surgery were retrospectively analyzed. All patients underwent radiotherapy, of which 74 patients received volumetric modulated arc therapy (VMAT), 9 patients received three-dimensional conformal radiation therapy (3DCRT), administered using a conventional segmentation protocol with a dose distribution range of 50.4–66.2Gy (median dose of 60Gy). In total, 41 patients received radiotherapy alone, 42 received radiotherapy combined with chemotherapy, and the concurrent chemotherapy regimen was mainly composed of either platinum or fluorouracil monotherapy, except for 4 patients who were given 5-fluorouracil plus platinum (FP) or paclitaxel plus platinum (TP). RESULTS: The median follow-up time was 24 (range, 9–75) months. The overall survival (OS) rates at 1 year, 2 years, 3 years, and 5 years were 83.0, 57.1, 40.1, and 35.1%, respectively. The median overall survival (OS) time was 18 (range, 5–75) months. The 3-year survival rate was 47.5% in patients with radiation alone and 41.9% in patients receiving concurrent chemoradiotherapy(p = 0.570), while the response rate (CR + PR) in those two groups was 73.2 and 91.4%, respectively. By multivariate analysis of OS, age (worse in younger patients, p = 0.034) was found to be significantly associated with disease prognosis. The commonly toxicities were esophagitis, neutropenia and anemia. 18% patients experienced grade 3 toxicity and no treatment-related death occurred. CONCLUSIONS: These results of this retrospective analysis suggest that radiotherapy with or without chemotherapy is an effective and feasible salvage treatment for lymph node recurrence after radical resection of esophageal squamous cell carcinoma. BioMed Central 2019-09-18 /pmc/articles/PMC6749665/ /pubmed/31533757 http://dx.doi.org/10.1186/s13014-019-1377-y Text en © The Author(s). 2019 Open AccessThis article is distributed under the terms of the Creative Commons Attribution 4.0 International License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated.
spellingShingle Research
Chen, Jie
Yin, Wenming
Yao, Hui
Gu, Wendong
Salvage treatment for lymph node recurrence after radical resection of esophageal squamous cell carcinoma
title Salvage treatment for lymph node recurrence after radical resection of esophageal squamous cell carcinoma
title_full Salvage treatment for lymph node recurrence after radical resection of esophageal squamous cell carcinoma
title_fullStr Salvage treatment for lymph node recurrence after radical resection of esophageal squamous cell carcinoma
title_full_unstemmed Salvage treatment for lymph node recurrence after radical resection of esophageal squamous cell carcinoma
title_short Salvage treatment for lymph node recurrence after radical resection of esophageal squamous cell carcinoma
title_sort salvage treatment for lymph node recurrence after radical resection of esophageal squamous cell carcinoma
topic Research
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6749665/
https://www.ncbi.nlm.nih.gov/pubmed/31533757
http://dx.doi.org/10.1186/s13014-019-1377-y
work_keys_str_mv AT chenjie salvagetreatmentforlymphnoderecurrenceafterradicalresectionofesophagealsquamouscellcarcinoma
AT yinwenming salvagetreatmentforlymphnoderecurrenceafterradicalresectionofesophagealsquamouscellcarcinoma
AT yaohui salvagetreatmentforlymphnoderecurrenceafterradicalresectionofesophagealsquamouscellcarcinoma
AT guwendong salvagetreatmentforlymphnoderecurrenceafterradicalresectionofesophagealsquamouscellcarcinoma